Modeling severe uncontrolled asthma: Transitioning away from health states

被引:0
作者
Lanitis, Tereza [1 ]
Khan, Asif H. [2 ]
Proskorovsky, Irina [3 ]
Houisse, Ivan [4 ]
Kuznik, Andreas [5 ]
Kamat, Siddhesh [5 ]
Franco-Villalobos, Conrado [3 ]
Joulain, Florence [2 ]
机构
[1] Tereza Lanitis Consulting Ltd, Methonis 1, CY-3071 Limassol, Cyprus
[2] Sanofi, 1 Ave Pierre Brossolette, F-91380 Chilly Mazarin, France
[3] Evidera, 7575 Trans canada Hwy,Suite 404, Quebec City, PQ H4T 1V6, Canada
[4] Evidera, Bocska ut 134-146 Eepulet 2 Emelet, H-1113 Budapest, Hungary
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
关键词
Asthma; Disease modeling; Discretely integrated condition event (DICE); Exacerbations; Lung function; LUNG-FUNCTION DECLINE; SEVERE EXACERBATIONS; UNITED-STATES; AIR-FLOW; MORTALITY; PREDICTORS; SIMULATION; BURDEN; LIFE;
D O I
10.1016/j.conctc.2024.101390
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Models developed to date to simulate long-term outcomes of asthma have been criticized for lacking granularity and ignoring disease heterogeneity. Objective: To propose an alternative approach to modeling asthma and apply it to model long-term outcomes in a population with moderate-to-severe type 2 asthma (patients with raised fractional exhaled nitric oxide or eosinophils) and treated with conventional therapy. Methods: A discretely integrated condition event (DICE) approach was adopted, simulating individual profiles with asthma over patients' lifetime in terms of exacerbations, asthma-related death, and death unrelated to asthma. The timing of these events is dependent on profile characteristics including lung function, asthma control, exacerbation history, and other baseline characteristics or contextual factors. Predictive equations were derived from a clinical trial to model time to exacerbation, change in asthma control, lung function, and utility. Real-world studies were used to supplement data gaps. Outcomes evaluated included life expectancy, qualityadjusted life-years (QALY), number of exacerbations, and lung function over time. Results: Average annual rates of severe and moderate exacerbations were 1.82 and 3.08 respectively, with rates increasing over time. Lung function declined at a higher rate compared with the general population. Average life expectancy was 75.2 years, compared with 82.4 years in a matched general population. The majority of life-years were spent with uncontrolled asthma and impaired lung function. Conclusion: Patients with moderate-to-severe type 2 asthma and a history of exacerbations suffer from frequent exacerbations and reduced lung function and life expectancy. Capturing multiple conditions to simulate longterm outcomes in patients with asthma may provide more realistic projections of exacerbation rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Predictors of exacerbations of asthma and COPD during one year in primary care
    Al-ani, Salwan
    Spigt, Mark
    Hofset, Per
    Melbye, Hasse
    [J]. FAMILY PRACTICE, 2013, 30 (06) : 621 - 628
  • [2] [Anonymous], 2018, The global asthma report 2018
  • [3] [Anonymous], 2017, Underlying Cause of Death 1999-2016 on CDC WONDER Online Database
  • [4] Severe exacerbations predict excess lung function decline in asthma
    Bai, T. R.
    Vonk, J. M.
    Postma, D. S.
    Boezen, H. M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2007, 30 (03) : 452 - 456
  • [5] Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
    Bleecker, Eugene R.
    Menzies-Gow, Andrew N.
    Price, David B.
    Bourdin, Arnaud
    Sweet, Stephen
    Martin, Amber L.
    Alacqua, Marianna
    Trung N Tran
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (03) : 276 - 293
  • [6] Clinical Burden and Predictors of Asthma Exacerbations in Patients on Guideline-based Steps 4-6 Asthma Therapy in the TENOR Cohort
    Calhoun, William J.
    Haselkorn, Tmirah
    Mink, David R.
    Miller, Dave P.
    Dorenbaum, Alejandro
    Zeiger, Robert S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2014, 2 (02) : 193 - U222
  • [7] Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics
    Caro, J. Jaime
    [J]. PHARMACOECONOMICS, 2016, 34 (07) : 665 - 672
  • [8] Discrete Event Simulation: The Preferred Technique for Health Economic Evaluations?
    Caro, Jaime J.
    Moeller, Joergen
    Getsios, Denis
    [J]. VALUE IN HEALTH, 2010, 13 (08) : 1056 - 1060
  • [9] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
    Castro, M.
    Corren, J.
    Pavord, I. D.
    Maspero, J.
    Wenzel, S.
    Rabe, K. F.
    Busse, W. W.
    Ford, L.
    Sher, L.
    FitzGerald, J. M.
    Katelaris, C.
    Tohda, Y.
    Zhang, B.
    Staudinger, H.
    Pirozzi, G.
    Amin, N.
    Ruddy, M.
    Akinlade, B.
    Khan, A.
    Chao, J.
    Martincova, R.
    Graham, N. M. H.
    Hamilton, J. D.
    Swanson, B. N.
    Stahl, N.
    Yancopoulos, G. D.
    Teper, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2486 - 2496
  • [10] Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]